myEDIT-B: an innovative blood test to distinguish forms of depression and accelerate diagnosis of bipolar disorder

Differentiating between forms of depression remains a major challenge, with the average diagnostic delay reaching 8 years. The myEDIT-B test, developed by ALCEDIAG and SYNLAB, combines RNA sequencing and artificial intelligence to provide a clinically validated and objective biomarker (>80% performance).

1. Evaluate the acceptability and usability of the test within Clariane’s networks (in France and Spain).
2. Promote the European pilot through a scientific publication and communications at international conferences.
3. Make preparations to implement the test clinically within the network’s psychiatric institutions (Inicea, Ita).

The psychiatrists who took part in the study highlight the test’s concrete impact on their practice: 

• 83% report that myEDIT-B helped them guide or redirect patients’ treatment;
• 100% believe that it has strengthened the therapeutic alliance with their patients;
• 67% consider that it has helped reduce the time to diagnosis;
• 92% indicate that it made communicating the diagnosis easier;
• 92% say it confirmed or disproved the initial diagnosis.
• These data reaffirm the value of integrating diagnostic tests into psychiatric care pathways to incorporate precision medicine.

• Pilot (63 patients, 12 psychiatrists): high satisfaction among prescribers (8.9/10) and patients (9/10).
• Promotion: ECNP 2025 poster, SEP 2025: “high acceptability and clinical utility”, article currently being prepared.
• Clinical implementation: adaptation of workflows and medico-economic assessment in 2026.

The real-world myEDIT-B acceptability study was conducted using a mixed design (quantitative and qualitative). 
It included 63 adult patients presenting a major, moderate or severe depressive episode at Clariane’s mental health clinic networks in France (Inicea) and Spain (Ita Salud Mental), as well as at Hospital Clínic de Barcelona, with the assistance of SYNLAB laboratories for biological analyses. 12 participating psychiatrists prescribed the myEDIT-B test as part of routine clinical management.